On this page
In short: mitochondria generate most cellular ATP through oxidative phosphorylation, but they also buffer calcium, initiate apoptosis, synthesise iron-sulphur clusters and act as signalling hubs. "Mitochondrial health" is shorthand for several separable things — how many mitochondria there are, how efficiently they convert fuel to ATP, how intact their membranes are, and how well damaged ones are cleared. Each is measured differently, and a compound can move one without touching the others.
- Mitochondria are signalling organelles as much as power plants — ATP output is one function among several.
- Decline is not one process: fewer mitochondria, disorganised cristae, leakier membranes, accumulated mtDNA damage and slower mitophagy are distinct failures with distinct measurements.
- The field's working measure is respirometry — oxygen consumption under sequential inhibitors, which separates ATP-linked respiration from proton leak and spare capacity.
- Research compounds act at different points in that chain: biogenesis, membrane structure, redox cofactor supply, or the electron transport chain itself.
- Nearly all of this evidence is preclinical, and a biomarker moving is not the same as function improving.
What mitochondria actually do
The textbook line — the powerhouse of the cell — is true and incomplete. Oxidative phosphorylation is the headline function: electrons stripped from nutrients pass down the electron transport chain embedded in the inner membrane, pumping protons into the intermembrane space to build an electrochemical gradient, which ATP synthase then discharges to phosphorylate ADP. A typical cell regenerates its own body weight in ATP daily through this machinery.
But the same organelle also does several other jobs that matter for how compounds affecting it behave:
- Calcium buffering. Mitochondria take up and release calcium, shaping cytosolic calcium signals and, through them, everything from muscle contraction to neurotransmitter release.
- Apoptosis. Permeabilisation of the outer membrane releases cytochrome c and commits the cell to programmed death. The organelle that powers the cell also decides when it stops.
- Reactive oxygen species as signal, not just damage. Electron leak generates superoxide. At low levels this is a signalling molecule driving adaptive responses; at high levels it is oxidative damage. The distinction is dose, not kind.
- Biosynthesis. Iron-sulphur cluster assembly, heme synthesis and steroidogenesis all begin or run through mitochondria.
- Innate immune signalling. Mitochondrial DNA released into the cytosol is recognised as a danger signal, tying mitochondrial damage directly to inflammation.
One structural detail is worth carrying forward: the inner membrane is folded into cristae, and that folding is not decorative. Cristae curvature organises the electron transport chain into supercomplexes and concentrates ATP synthase at the tips. Lose the folding and you lose efficiency, independent of how many mitochondria are present. This is why several compounds in the research literature target membrane architecture rather than metabolism.
What "declining mitochondrial health" actually means
The phrase compresses at least five distinct failures. Distinguishing them matters, because an intervention that addresses one may do nothing for the others.
Fewer mitochondria (reduced biogenesis)
Mitochondrial mass is regulated largely through the PGC-1α transcriptional programme, which responds to energy stress, cold and exercise. Its activity falls with age and inactivity, and mitochondrial content falls with it.
Disorganised cristae
Cristae remodelling appears in ageing tissue, heart failure and mitochondrial myopathies. Flattened or fragmented cristae destabilise respiratory supercomplexes and reduce ATP output per unit of mitochondrial mass.
Accumulated mtDNA damage
Mitochondrial DNA sits close to the source of reactive oxygen species, has limited repair capacity, and is present in many copies per cell. Damaged copies accumulate with age, and above a threshold fraction they impair the respiratory complexes they encode.
Redox cofactor depletion
NAD+ is the electron acceptor that makes the citric acid cycle run, and it is also consumed by sirtuins and PARPs during stress and DNA repair. Tissue NAD+ falls with age across multiple species — a finding that has driven a large share of current mitochondrial research.
Impaired quality control
Damaged mitochondria are normally tagged and cleared by mitophagy, then replaced. When clearance slows, dysfunctional organelles persist, leaking electrons and calcium. The failure here is not production but disposal.
Consumer content treats "mitochondrial health" as a single dial. The research does not. Reading a compound's evidence sensibly means asking which of the five failures above it was tested against, and in what model.
How mitochondrial function is measured
If you are evaluating a claim about a compound, this is the section that does the work. Each readout answers a different question, and the assay used tells you what the finding can and cannot support.
| Measurement | Method | What it tells you |
|---|---|---|
| Oxygen consumption rate | Extracellular flux analysis (Seahorse) or high-resolution respirometry, with sequential oligomycin, FCCP and rotenone/antimycin A | Separates basal respiration, ATP-linked respiration, proton leak, maximal capacity and spare respiratory capacity — the closest thing to a direct functional measure |
| Membrane potential | Potentiometric dyes — TMRM, JC-1 | Whether the proton gradient that drives ATP synthesis is intact; collapse precedes most forms of dysfunction |
| Mitochondrial content | mtDNA copy number by qPCR; citrate synthase activity | How many mitochondria are present — a biogenesis readout, not an efficiency one |
| Reactive oxygen species | MitoSOX and related targeted probes | Superoxide production at the source, distinguishing mitochondrial from cytosolic oxidative load |
| Cristae architecture | Transmission electron microscopy; supercomplex analysis by blue native PAGE | Structural integrity — the variable membrane-targeted compounds are designed to move |
| ATP concentration | Luciferase-based luminescence assays | Endpoint output, though it reflects both production and consumption |
| Biogenesis signalling | PGC-1α, TFAM, NRF1 expression | Whether the transcriptional programme for building mitochondria has been engaged |
The practical lesson: a study reporting raised PGC-1α expression has shown that a biogenesis programme was switched on, not that the cell ended up making more ATP. A study reporting increased spare respiratory capacity has shown something much closer to function. Both are legitimate findings; they are not equivalent claims.
Compounds studied for mitochondrial function
Several compounds in our catalogue appear in the mitochondrial literature, acting at genuinely different points in the chain described above. The pips indicate how developed the evidence base is — three for compounds with human clinical data, two for reproduced animal work, one for primarily cell-based or single-study findings.
MOTS-c — a peptide encoded by the mitochondrion itself
MOTS-c is one of the more conceptually interesting molecules in this space: a short peptide encoded not in nuclear DNA but within the mitochondrial genome itself, identified in 2015. It signals outward rather than inward, activating AMPK and influencing the folate–methionine cycle, and has been characterised in the literature as an exercise mimetic. In rodent work it improved insulin sensitivity and metabolic flexibility, and circulating levels rise with exercise. A later study reported improved physical performance in older mice. The work is well replicated in animals; human data remains limited.
SS-31 — targeting the membrane, not the metabolism
SS-31 takes the structural route. It associates with cardiolipin, the signature phospholipid of the inner mitochondrial membrane, and in doing so stabilises cristae curvature and respiratory supercomplex assembly — improving the efficiency of electron transport rather than its raw throughput, and reducing electron leak in the process. It is among the very few compounds here with genuine clinical trial data, having been studied as elamipretide in primary mitochondrial myopathy, Barth syndrome and heart failure. Those trials produced mixed results, with some missing their primary endpoints, which is worth knowing alongside the strong preclinical rationale.
NAD+ — the cofactor everything else depends on
NAD+ is not a drug but a coenzyme, and it sits upstream of nearly everything discussed here: it carries the electrons the transport chain consumes, and it is the substrate sirtuins need to regulate mitochondrial gene expression. Tissue levels decline with age, and restoring them is one of the most active areas in the field. One honest caveat belongs here: most human work uses precursors such as nicotinamide riboside or NMN rather than NAD+ itself, because the intact molecule is poorly absorbed. Those trials reliably raise blood NAD+ levels; whether that translates into functional improvement is much less settled.
Methylene blue — an alternative electron carrier
Methylene blue does something none of the others do: at low concentrations it acts as an artificial electron shuttle, accepting electrons from NADH and delivering them to cytochrome c, effectively bypassing part of the transport chain. In models where complex I is impaired, that bypass is the entire point. Its behaviour is strongly biphasic — the same molecule that supports respiration at low concentrations inhibits it at higher ones — which makes concentration-response characterisation essential in any experiment using it, and makes results from one concentration a poor guide to another.
SLU-PP-332 — switching on the biogenesis programme
SLU-PP-332 is an agonist at the oestrogen-related receptors, a family of nuclear receptors governing mitochondrial biogenesis and fatty acid oxidation. In mouse work it increased exercise capacity and upregulated the oxidative gene programme without exercise, which is why it is described as an exercise mimetic in the literature. The evidence is recent and animal-based, but the mechanism sits squarely on the biogenesis axis.
5-Amino-1MQ — an indirect route to NAD+
5-Amino-1MQ inhibits nicotinamide N-methyltransferase, an enzyme that methylates nicotinamide and in doing so consumes both a NAD+ precursor and a methyl donor. Inhibiting it has been studied as a way to preserve NAD+ salvage capacity, with the most-cited work in adipose tissue of obese mice. Its relationship to mitochondrial function is real but indirect — upstream of cofactor availability rather than acting on the organelle.
| Compound | Point of action | Evidence base |
|---|---|---|
| SS-31 | Cardiolipin binding; cristae and supercomplex stability | Human trials, mixed results |
| NAD+ | Redox cofactor supply; sirtuin substrate | Human trials, mostly of precursors |
| MOTS-c | AMPK activation; mitochondrial-derived signalling | Reproduced animal work |
| Methylene Blue | Alternative electron carrier, NADH to cytochrome c | Animal and cell work; strongly concentration-dependent |
| SLU-PP-332 | ERR agonism; mitochondrial biogenesis programme | Recent animal work |
| 5-Amino-1MQ | NNMT inhibition; upstream of NAD+ salvage | Animal work, indirect mechanism |
Read across that table and a pattern emerges: these compounds are not interchangeable. SS-31 and methylene blue act on existing mitochondria; SLU-PP-332 tries to build more; NAD+ and 5-Amino-1MQ address cofactor supply; MOTS-c signals through a stress-response pathway. An experiment designed around one is not a test of another.
What the research does not show
- Most of it is preclinical. Cell and rodent models dominate, and mitochondrial biology translates across species imperfectly.
- Biomarkers are not outcomes. Raised mtDNA copy number, higher PGC-1α or increased blood NAD+ are measurements of a mechanism, not demonstrations of benefit.
- Hormesis complicates everything. Mild mitochondrial stress triggers adaptive responses that improve function; more of the same stress causes damage. Compounds acting on this axis frequently show inverted-U responses, so a result at one concentration predicts little about another.
- "Mitochondrial health" is not a single endpoint. Without specifying which failure mode is being addressed, the phrase carries no testable meaning.
- Tissue specificity is routinely ignored. Mitochondrial density and demand differ enormously between heart, brain, skeletal muscle and adipose. A finding in one tells you comparatively little about another.
All compounds discussed here are supplied strictly for laboratory and in-vitro research. They are not medicines, are not for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any disease. Nothing in this article is medical advice or a protocol for administration.
Frequently asked questions
What is mitochondrial health?
An umbrella term for several separable properties: how many mitochondria a cell contains, how efficiently they convert fuel into ATP, whether their membranes and cristae are intact, how much reactive oxygen species they leak, and how effectively damaged ones are cleared and replaced. Each is measured by a different assay.
How is mitochondrial function measured in research?
Most directly by respirometry — measuring oxygen consumption while sequentially adding inhibitors to separate ATP-linked respiration, proton leak and maximal capacity. Supporting measures include membrane potential dyes, mtDNA copy number, citrate synthase activity, targeted ROS probes and electron microscopy of cristae.
What causes mitochondrial function to decline?
Reduced biogenesis signalling, disorganised cristae, accumulated mitochondrial DNA damage, depletion of NAD+ and other redox cofactors, and impaired mitophagy. These are distinct processes, and an intervention addressing one may not affect the others.
Which research compounds act on mitochondria?
Those discussed here act at different points: SS-31 on inner membrane structure, NAD+ on cofactor supply, MOTS-c through AMPK signalling, methylene blue as an alternative electron carrier, SLU-PP-332 on the biogenesis programme, and 5-Amino-1MQ upstream of NAD+ salvage.
Is NAD+ the same as its precursors?
No. Most human research uses precursors such as nicotinamide riboside or NMN rather than NAD+ itself, because the intact molecule is poorly absorbed. Those trials consistently raise measured NAD+ levels; functional outcomes are far less consistent.
Selected reading
Starting points in the primary literature — each title links to its record on PubMed. These are provided for reference and are not endorsements of any particular finding.
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015.
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021.
- Birk AV, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 2013.
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 2014.
- Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science, 2015.
- Wen Y, et al. Methylene blue improves mitochondrial respiration and decreases oxidative stress in a substrate-dependent manner. Drug Development Research, 2011.
- Billon C, et al. A synthetic ERR agonist alleviates metabolic syndrome. Journal of Pharmacology and Experimental Therapeutics, 2024.
- Kraus D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 2014.
Continue reading
Purity and identity confirmed by independent analysis, individually lot-tracked, with the full report published before listing.
This article is provided for educational and informational purposes only and is based on published research. Core Labs supplies research chemicals for laboratory use exclusively. Products are not approved for human consumption, nor for medical, veterinary or household use.